Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of HLX43 in advanced non-small cell lung cancer
CTR20251144Phase 2Active
- Sponsor
- HyBioPharma
- Start
- Jun 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HLX43 in non-small cell lung cancer (NSCLC), sponsored by HyBioPharma. Started Jun 2025; status: active.
02
Drugs
HLX43
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20251144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251144.